malignancy screening in esrd patients
DESCRIPTION
Malignancy screening in ESRD patients. Dr. Weal Habhab,MD,FRCPC Nephrology Consultant Nephrology Section Head King Faisal Specialist Hospital -Jeddah. eGFR and risk of cancer death. Risk of cancer in ESRD. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/1.jpg)
Malignancy screening in ESRD patients
Dr. Weal Habhab,MD,FRCPCNephrology Consultant
Nephrology Section HeadKing Faisal Specialist Hospital -Jeddah
![Page 3: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/3.jpg)
Risk of cancer in ESRD Controversial, but it is reported to be higher in
ESRD compare to general population Lancet,1999: international study indicated the
standardized incidence ratio(SIR) of cancer to be 1.18 higher in ESRD patients.
NDT,2011: study from Taiwan showed the SIR to be 1.4 in 4328 patients in 4.4 years follow up study.
![Page 4: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/4.jpg)
Observations The risk was higher in
o Younger patients <35
o Female patients
o In the first year of dialysis
![Page 5: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/5.jpg)
The over all risk of cancer
Number of new cancer cases SIR 95% CI
All patients 4328 1.4 1.3–1.4 Male 2069 1.2 1.1–1.3 Female 2259 1.6 1.5–1.7Age at first dialysis
0–34 years 129 9.2 5.3–16.0
35–54 years 1433 3.5 3.1–3.9
55–65 years 1180 1.7 1.6–1.9
≥65 years 1586 0.8 0.7–0.8
Time after first dialysis
Year 1 723 8.3 7.6–9.0 Year 2 735 3.9 3.6–4.2 Year 3 672 2.9 2.7–3.1 Year 4 581 2.0 1.9–2.2 Year 5 467 1.6 1.5–1.8 Years 6–8 822 1.0 0.9–1.1 >Year 8 328 0.3 0.2–0.3
![Page 6: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/6.jpg)
Predisposing factors Acquired renal cystic disease
Medication , CYP
Infections, HBV and HCV
Human papilloma virus
![Page 7: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/7.jpg)
Mechanism Controversial :
o Infections
o Prolonged chronic uremia impair T-cells and APC functions
o Nutritional abnormality like Vit D deficiency and selenium deficiency
![Page 8: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/8.jpg)
Top cancer in ESRD Bladder Kidney Liver Cervix Tounge
![Page 9: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/9.jpg)
Prognosis USRDS 2007, showed the risk of death from
cancer among ESRD to be 7 deaths per 1000 patients.
While cardiac arrest resulted in 38 deaths per 1000 patients at the same period.
![Page 10: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/10.jpg)
Screening of cancer among ESRD patients
Benefits
High mortality from non-malignant causes
![Page 11: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/11.jpg)
Screening One study examined the benefits of
mammography, PSA, sigmodiscopy and pap smear as screening tools among ESRD and showed ,o The costs per unit of survival benefit conferred by cancer
screening were 1.6 to 19.3 times greater among patients with ESRD compared with the general population
o The net gain of life expectancy in patients with ESRD via these screening programs was calculated to be five days or less. Similar survival gains could be obtained by reducing the baseline ESRD mortality rate by 0.02 percent.
![Page 12: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/12.jpg)
Screening tests routine cancer screening in the ESRD population
did not represent an efficient allocation of financial resources
Similar findings were reported in a study evaluating the efficacy of breast and cervical cancer screening of Canadian women undergoing maintenance dialysis.
![Page 13: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/13.jpg)
Screening tests Colorectal cancer:In one series, the incidence of guaiac positive stools was three times higher in asymptomatic dialysis patients compared with non-ESRD controls .
Nevertheless, the presence of a positive stool guaiac test in an asymptomatic individual with ESRD may permit the early discovery of a colorectal malignancy .
![Page 14: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/14.jpg)
Screening test Prostate cancer
o Screening with PSA still controversial in general population.
o A higher incidence of prostate cancer among patients with ESRD has been reported .
o Serum PSA levels do not appear to be affected by renal failure
.o But it is not cost effective except in pretransplant
evaluation
![Page 15: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/15.jpg)
Screening test Cervical cancer
o The standardized incidence ratio of cervical cancer among
ESRD patients is approximately 2.5 to 4 times that in the normal population o This higher risk is due primarily to the increased
presence of the human papilloma virus (HPV) in this patient population.
![Page 16: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/16.jpg)
Cervical cancero Pap smear screening beginning at age 21 years of age
o HPV DNA testing and HPV vaccine, especially in transplant candidates
o Yearly Pap test in those on transplant waiting lists and in
patients with risk factors and long expected survival based on demographic factors and comorbid conditions affecting survival in ESRD.
![Page 17: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/17.jpg)
Screening tests Breast cancer
o Yearly mammograms and breast examinations for women >40 years of age and on transplant waiting lists would be reasonable.
![Page 18: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/18.jpg)
Screening tests Renal cell carcinoma Acquired cystic disease is premalignant condition The incidence is 22% in patient on maintenance
dialysis The incidence of RCC as complication of acquired
cystic disease varies between 2-4% yearly screening for acquired cystic disease with
US to be performed in patients who have been on dialysis for three to five years
![Page 19: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/19.jpg)
Screening tests Tumor markers:
o The accuracy of other tumor markers in ESRD patients is unknown.
o They are of high molecular weight and ineffectively removed by dialysis, giving highly false positive rate.
o Still alpha- fetoprotein ,PSA of high value
![Page 20: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/20.jpg)
Summery Practice guidelines and/or standards for cancer
screening that have been developed in the general population are not necessarily applicable to patients with end-stage renal disease (ESRD).
Cancer screening protocols are best implemented on an individual patient basis.
Special consideration should be given to patients on transplant list
Routine cancer screening is perhaps most inappropriate in patients with ESRD who are diabetic, white, or ≥65 years of age.
![Page 21: Malignancy screening in ESRD patients](https://reader036.vdocuments.mx/reader036/viewer/2022081517/56816676550346895dda1400/html5/thumbnails/21.jpg)
Thank you